From the publishers of JADPRO

DLBCL Resource Center

Advertisement

Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma

Last Updated: Tuesday, April 12, 2022

Data from a multicenter, prospective study of elderly patients with newly diagnosed DLBCL who underwent baseline comprehensive geriatric assessment demonstrated that an impairment of instrumental activities of daily living was independently associated with grade 3/4 leukopenia (OR 0.63; 95% CI, 0.43-0.92; P = 0.017) and anemia (OR 0.67; 95% CI, 0.50-0.90; P = 0.008). In addition, presence of a comorbidity was associated with grade 3/4 nonhematological toxicity (OR 2.17; 95% CI, 1.37-3.43; P = 0.001).

Scientific Reports
Advertisement
News & Literature Highlights

European Society for Medical Oncology (ESMO) Congress 2024 Abstract

806MO - Phase Ib study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)

2024 American Society of Hematology Annual Meeting Abstract

Waveline-007: Dose escalation and confirmation, and efficacy expansion trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in patients with diffuse large B cell lymphoma

2024 American Society of Hematology Annual Meeting Abstract

Open-label phase 2 study results of FS118, a LAG-3/PD-L1 bispecific antibody, in patients with relapsed/refractory diffuse large B-cell lymphoma

2024 American Society of Hematology Annual Meeting Abstract

Time of CAR-T failure is a strong predictor of outcome for bispecific antibody therapy in relapsed/refractory large B-cell lymphoma

2024 American Society of Hematology Annual Meeting Abstract

Real-world effectiveness of tafasitamab (Tafa) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) in the United States

2024 American Society of Hematology Annual Meeting Abstract

Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes

The Oncologist

Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphoma 

Bone Marrow Transplantation

Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: A multicenter study

Medpage Today

New antibody-drug conjugate OK'd in DLBCL

Journal of Clinical Oncology

Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial

Advertisement
Advertisement